Prescription drug · BLA
Vpriv (Velaglucerase alfa) NDC 54092-701
Velaglucerase alfa 2.5 mg/mL · Injection, Powder, Lyophilized, For solution · Intravenous · Takeda Pharmaceuticals America, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 54092-701-04 | 5409207010454092070104 | 1 VIAL, GLASS in 1 BOX (54092-701-04) / 4 mL in 1 VIAL, GLASSMarketed from Feb 26, 2010 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Vpriv
- Generic name (nonproprietary)
- velaglucerase alfa
- Active ingredients
- Velaglucerase alfa — 2.5 mg/mL
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Intravenous
- Labeler
- Takeda Pharmaceuticals America, Inc.NDC labeler code 54092
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 022575
- Marketing start
- Listing expires
- Identifiers
- Product ID 54092-701_27f96d8e-a6e0-4743-a76c-00f979bfb5f7SPL ID 27f96d8e-a6e0-4743-a76c-00f979bfb5f7SPL set ID ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cfRxCUI 901808, 901812UNII 23HYE36B0I
- Pharmacologic class
- Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N454092070104followed by a unit qualifier and the quantityPackage 54092-0701-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 54092-701
- What is NDC 54092-701?
- 54092-701 is the product NDC for Vpriv (velaglucerase alfa), Velaglucerase alfa 2.5 mg/mL injection, powder, lyophilized, for solution, listed with the FDA by Takeda Pharmaceuticals America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Vpriv (Velaglucerase alfa).
- What is the active ingredient?
- Velaglucerase alfa.
- Who is the labeler?
- Takeda Pharmaceuticals America, Inc., NDC labeler code 54092. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Vpriv?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.